DeepHealth has acquired Kheiron Medical Technologies Limited, a UK-based AI cancer diagnostic company focused on developing deep learning solutions to support radiologists improve breast cancer detection. Kheiron’s Mia® (Mammography Intelligent Assessment) suite of AI solutions for breast cancer screening is a strong fit with DeepHealth’s portfolio roadmap aimed at large-scale diagnostic and screening programs leveraging AI-powered health informatics solutions.
“Finding cancer in its earliest stages gives patients a greater chance of survival. At DeepHealth, we are passionate about the meaningful role we can play in cancer detection. The acquisition of Kheiron will further expand our portfolio of AI-powered diagnostic and screening solutions, enabling us to accelerate the introduction of our breast cancer solutions in Europe,” said Sham Sokka, PhD, Chief Operating and Technology Officer DeepHealth.
DeepHealth’s existing portfolio includes an AI-powered, cloud-native, end-to-end solution for breast cancer diagnosis – Smart Mammo™. The solution supports high-volume screening programs, such as the successful Enhanced Breast Cancer Detection (EBCD) program of RadNet, a leading provider of diagnostic imaging in the United States. Kheiron’s CE-marked technology, Mia™, delivers double-reading quality with a single human reader. Mia™ was deployed in the EU and UK’s first prospective evaluation of a breast screening AI solution, showing impressive results. Kheiron’s technology and clinical validation will complement DeepHealth’s portfolio and enrich its capabilities and network of customers and partners.
“Our mission to improve breast cancer outcomes has always been a global one. As part of DeepHealth, we will be able to give many more women a better fighting chance against breast cancer,” said Peter Kecskemethy, Co-founder Kheiron. “Together, we will be even better positioned to equip radiologists with the tools they need to detect even the most subtle lesions and further optimize breast cancer screening,” he added.
Founded in 2016, Kheiron is headquartered in London, United Kingdom. The company combines novel deep learning methods and radiology insights to find malignancies in mammograms and enable improved efficiency, consistency, and accuracy of radiology reporting.